<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03284853</url>
  </required_header>
  <id_info>
    <org_study_id>PG324-CS303</org_study_id>
    <nct_id>NCT03284853</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Prospective, Double-masked, Randomized, Multicenter, Active-controlled, Parallel-group, 6-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to GANFORT® (Bimatoprost 0.03% / Timolol 0.5%) Ophthalmic Solution in Subjects With Elevated Intraocular Pressure (MERCURY 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerie Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerie Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02%
      / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP)
      in patients with elevated intraocular pressure
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean diurnal Intraocular Pressure by Goldmann Applanation Tonometry</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of anterior segment tissues by slit lamp biomicroscopy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of posterior segment tissues by dilated ophthalmoscopy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic safety of vital signs (heart rate/bpm)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic safety of vital signs (blood pressure/systolic diastolic mmHg)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic safety clinical laboratory assessments (hematology and clinical chemistry)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Intraocular Pressure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">472</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Netarsudil/Latanoprost 0.02%/0.005%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.0005%) one drop daily to each eye for 180 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GANFORT®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil/Latanoprost 0.02%/0.005%</intervention_name>
    <description>Topical sterile ophthalmic solution</description>
    <arm_group_label>Netarsudil/Latanoprost 0.02%/0.005%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GANFORT®</intervention_name>
    <description>Topical sterile ophthalmic solution</description>
    <arm_group_label>GANFORT®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be 18 years or older

          2. Diagnosis of Open Angle Glaucoma or Ocular Hypertension

          3. Participants insufficiently controlled and/or considered in need for combination
             therapy

          4. Medicated intraocular pressure (IOP) greater than 18 mmHg and less than 25 mmHg in
             both eyes at screening visit

          5. Unmedicated (post-washout) IOP greater than 20mmHg and less than 36mmHg in both eyes
             at two qualification visits

          6. Best corrected visual acuity +1.0 logMAR or better

          7. Be willing and able to give informed consent and follow instructions

          8. Women must be either of non-child bearing potential, or women with child bearing
             potential and men with reproductive potential must be willing to practice acceptable
             methods of birth control during the study

          9. Women of child bearing potential must have a negative urine pregnancy test within 7
             days of first dose of study treatment and agree to use highly effective contraception
             from time of randomization and for 3 months after last dose of study medication

         10. Men with a female partner of childbearing potential must have either had a prior
             vasectomy or agree to use effective contraception from time of randomization and for 3
             months following the last dose of study medication

         11. In France, a subject will be eligible for inclusion in this study only if either
             affiliated to or as a beneficiary of a social security number

        Exclusion Criteria:

        Ophthalmic

          1. Clinically significant ocular disease which might interfere with interpretation of the
             study results, including subjects with glaucomatous damage so severe that washout of
             ocular hypotensive medication for four weeks or longer would not be judged as safe

          2. Pseudoexfoliation or pigment dispersion glaucoma, history of narrow angles or angle
             closure glaucoma. Previous laser peripheral iridotomy is not permitted

          3. IOP greater than or the same as 36mmHg (unmedicated) in either eye or the use of more
             than two ocular hypotensive medications within 30 days of screening

          4. Treatment-naïve subjects

          5. Prior treatment with GANFORT® topical eye drops

          6. Known hypersensitivity to any component of the investigational formulations to be used

          7. Previous glaucoma intra ocular surgery

          8. Refractive surgery in either eye

          9. Ocular trauma within 6 months prior to screening, or ocular surgery or non- refractive
             laser treatment within 3 months prior to screening

         10. Recent or current evidence of ocular infection or inflammation in either eye.

         11. Use of ocular medication in either eye within 30 days of screening and throughout the
             study with the exception of permitted ocular medication as prescribed by the
             investigator

         12. Mean central corneal thickness greater than 620μm at screening

         13. Any abnormality preventing reliable Goldmann applanation tonometry of either eye

             Systemic

         14. Clinically significant abnormalities in laboratory tests at screening

         15. Known hypersensitivity or contraindication to GANFORT® and to β-adrenoceptor
             antagonists

         16. Clinically significant systemic disease which might interfere with the study

         17. Participation in any investigational study within 30 days prior to screening

         18. Systemic medication that could have a substantial effect on IOP within 30 days prior
             to screening, or anticipated during the study

         19. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or
             not using a medically acceptable and highly effective form of birth control

         20. Vulnerable subjects such as minors, adults under legal protection or unable to express
             their consent, persons deprived of liberty or persons subject to psychiatric care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Herring</last_name>
    <role>Study Director</role>
    <affiliation>Aerie Pharmaceuticals Ireland Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Herring</last_name>
    <phone>888-594-5111</phone>
    <email>mercury3@aeriepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>State Hospital - University Medical Center Academical Department of Ophthalmology</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albertgasse 39/10+11</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Sint Rafael</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Service Centre Francois Xavier Michelet CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre ophtalmologique Pole vision val d'ouest</name>
      <address>
        <city>Ecully</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Service - Batiment R Hospital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes-Hospital Hotel Dieu Ophthalmology Service</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ophthalmology department Necker University Hospital-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Freiburg</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology Clinical Johannes Gutenberg-University Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Private Praxis</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Eye Hospital Tuebingen, STC eyetrial at the center for Ophthalmolgy</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Clinic DiNOGMI University Hospital San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dept. Ophthalmology, San Raffaele Hospital</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli Sacco P.O.L.Sacco</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Santi Paolo e Carlo - Ophthalmic Clinic</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Medicine and Surgery University of Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ophthamic Clinic of the University of Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Pisana Hospital of Cisanello</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Britannico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Senese University Hospital</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eye Clinic- Maggiore Hospital University of Trieste</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Politecnico Gianbattista Rossi AOUI Ospedale Borgo Roma</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Oftalmologia Barraquer</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General de Catalunya Ophthalmology Department</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital QuironSalud Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Catala de retina (ICR) Glaucoma and Investigation Department</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía de Córdoba</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General del S.A.S. de Jerez de la Frontera</name>
      <address>
        <city>Jerez</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Ojos de la Coruña</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Tajo Glaucoma Department</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena Ophthalmology Department</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Torrevieja Ophthalmology Department</name>
      <address>
        <city>Torrevieja</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FISABIO-Oftalmología Médica</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Department Hospital Universitario Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa Zaragoza Ophthalmology department</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet Ophthalmology Department</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NHS Grampian Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid-Cheshire Hospitals NHS Foundation Trust</name>
      <address>
        <city>Crewe</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Anglia NHS Foundation trust Hinchingbrooke Hospital</name>
      <address>
        <city>Huntingdon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas' NHS Foundation Trust Glaucoma Research Area</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southampton National Institute for Health Research</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Hospitals Sunderland NHS Foundation Trust Sunderland Eye Infirmary</name>
      <address>
        <city>Sunderland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Cornrwall Hospitals NHS</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Cloprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

